- CVS Health raised its full-year adjusted EPS forecast to a range of $6 to $6.20, up from the previous $5.75 to $6, surpassing analyst estimates.
- The company expects 2025 EPS to be between $4.23 and $4.43, previously seen at $4.58 to $4.83.
- Projected cash flow from operations is set at $7 billion, slightly under the $7.63 billion estimate but higher than the previously forecasted $6.5 billion.
- In the first quarter, CVS reported an adjusted EPS of $2.25, significantly higher than last year’s $1.31 and above the $1.69 estimate.
- Comparable sales grew by 14.2%, outperforming the expected 9.04% rise.
- Net revenue reached $94.59 billion, reflecting a 7% year-over-year increase and beating the $93.58 billion forecast.
- Healthcare Benefits revenue increased by 8% to $34.81 billion, above the estimated $33.22 billion.
- Pharmacy network revenues surged by 13% to $23.11 billion, exceeding the $22.43 billion expectation.
- Adjusted operating income rose by 55% year-over-year to $4.58 billion, significantly higher than the $3.68 billion estimated.
- The EPS increase was driven by improved performance in the Health Care Benefits segment, particularly in Medicare operations.
- CVS Health’s 2025 guidance reflects robust business performance but remains cautious due to cost trends and potential economic challenges.
- CVS Caremark is partnering with Novo Nordisk to enhance access to the medication Wegovy for its members at a lower cost.
- The company will make Wegovy a preferred formulary medication starting July 1.
- CVS plans to exit the individual exchange business managed by Aetna’s ACA plans by 2026, with continued support through 2025.
Cvs Health Corp on Smartkarma
Analysts on Smartkarma have been closely covering CVS Health Corp, providing valuable insights on the company’s performance and future prospects. Baptista Research, in their report “CVS Health: $97.7 Billion Revenue and a New CEO – Can It Overcome Industry Challenges?“, highlighted the company’s recent turnaround with better-than-expected earnings, leading to a significant stock price surge. Despite challenges faced in 2024, including regulatory scrutiny and financial pressures, the appointment of a new CEO has instilled confidence in investors.
On the contrary, Value Investors Club took a bearish stance in their report “Cvs Health Corp (CVS) – Thursday, Oct 3, 2024″, citing concerns over declining performance in Pharmacy & Consumer Wellness operations. They suggested possible downside for CVS and recommended pair trades to hedge risks. In another report by Baptista Research, “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers“, the company’s revenue growth was highlighted despite challenges in the Health Care Benefits segment, showcasing a multifaceted view of CVS Health Corp’s strategic direction.
A look at Cvs Health Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, CVS Health Corp shows a strong outlook for the future. With high scores in Value and Dividend, the company is considered a solid investment in terms of its financial health and commitment to rewarding investors. Additionally, CVS Health Corp has received a top score in Momentum, indicating a positive trend in its stock performance. However, the company’s Growth and Resilience scores are slightly lower, suggesting potential areas for improvement. Overall, CVS Health Corp’s integrated pharmacy health care services and nationwide presence position it well for long-term success.
As an integrated pharmacy health care provider, CVS Health Corporation offers a wide range of services, including pharmacy benefit management, retail and specialty pharmacy, disease management programs, and retail clinics across the U.S., the District of Columbia, and Puerto Rico. With strong scores in Value, Dividend, and Momentum, CVS Health Corp demonstrates promising prospects for investors seeking stability and growth in the healthcare sector. Despite lower scores in Growth and Resilience, the company’s established presence and diversified offerings make it a compelling choice for long-term investment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
